An interventional study of SMS reminders to enhance colorectal cancer screening and SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening: in Mass Screening, Colorectal Cancer and Breast Cancer, sponsored by Institut Català d'Oncologia. Completed at 1 site in Spain. Open to participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Institut Català d'Oncologia · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.
Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 2nd largest by enrollment of the 405 interventional ones that give a count, is one of 40 that started in 2021, is one of 61 with no phase, and was the 254th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Verastem, Inc. · Sites in Spain, United States, Australia and 2 more countries
Ages 18+
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
AbbVie · Sites in Spain, United States, Belgium and 8 more countries
Ages 18+
Gilead Sciences · Sites in Spain, United States, Australia and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 50 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 146 · Phase 2 192 · Phase 3 73 · Phase 4 7
First in 1993; this study’s year is marked. 40 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44,601 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 167 across the 405 interventional studies, 400 across the 55 observational. Of the 282 that completed or were terminated, 125 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
300 of 463 have an industry lead sponsor. The 10 most frequent:
Institut Català d'Oncologia is the lead sponsor of 35 studies on the registry; 6 are open to participants now.
Institut Català d'Oncologia has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
41 of the studies in Colorectal Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT05988645MiWEndo Solutions S.L.Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II) | 2026-11-29 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 463 studies in Colorectal Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this project is to assess the impact on health and economics of the implementation of text messaging (SMS) in cancer screening programs. Three interventions with SMS will be evaluated through community trials. In the colorectal cancer screening program the following interventions will be tested: a) Participation reminder: six weeks after sending the invitation letter of the colorectal cancer program if there has not been a response, a reminder SMS will be sent in front of the usual method by letter; b) Reminder to return the fecal occult blood test: SMS reminder of test delivery versus no intervention. This reminder will be sent to the individuals who have gone to the pharmacy to pick up a fecal occult blood test and they have not returned it after 14 days. The impact on participation will be analyzed and, if applicable, the proportion of advanced neoplasms will be calculated by increase in participation. In the breast cancer screening program, the invitation by SMS versus the usual invitation by letter will be studied in women who had participated in the previous screening round. The impact on participation will be analyzed. A cost-effectiveness analysis of the three interventions will be carried out. The incremental cost ratio of the interventions between cost variation and effectiveness variation will be calculated.
Main Hypothesis:
The implementation of SMS in population-based cancer screening programs will improve participation, especially in colorectal cancer screening, will allow a better resource management and reduce costs in both programs.
Specific Hypothesis:
Sending the reminder SMS will have an impact on participation greater than that obtained with the standard reminder (letter) in the colorectal cancer screening program.
The effect of the colorectal cancer screening reminder SMS will be greater among the individuals who have been invited for the first time and not previous participants.
Participation after receiving the invitation by SMS in breast cancer screening will be equal to or better than the letter invitation.
The alternative that includes sending SMS will be cost-effective in relation to the current alternative that you use postal shipping.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
Behavioral: SMS reminders to enhance colorectal cancer screening
Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
Behavioral: SMS reminders to enhance colorectal cancer screening
SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
Behavioral: SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:
No reminders will be sent.
Behavioral: SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:
Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
Behavioral: Invitation by SMS to previous participants in breast cancer screening:
Letter invitations will be sent.
Behavioral: Invitation by SMS to previous participants in breast cancer screening:
Individual randomization will be used. Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis).
Also known as: Intervention 1
Individual randomization will be used. Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis).
Also known as: Intervention 2
Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
Also known as: Intervention 3
Intervention 1: Participation in colorectal cancer screening program
Participation (no/yes) will be gathered prospectively 18 weeks after sending the screening invitation letter (week 0).
Time frame: 18 weeks
Intervention 2: Participation in colorectal cancer screening program among individuals who pick the test at the pharmacy
Participation (no/yes) among those individuals who pick the screening test for colorectal cancer at the pharmacy 18 weeks after sending the screening invitation letter (week 0).
Time frame: 18 weeks
Intervention 3: Participation in breast cancer screening program
Participation (no/yes) will be gathered prospectively 8 weeks after sending the screening invitation letter (week 0).
Time frame: 8 weeks
Incremental cost ratio
A cost-effectiveness analysis of the three interventions will be carried out. The incremental cost ratio of the interventions between cost variation and effectiveness variation will be calculated.
Time frame: 18 weeks
Plan to share: No
Ran from Jun 2021 to primary completion in Oct 2022, 16 months.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 16 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Català d'Oncologia